Development and Evaluation of MedMixBot: A Chatbot for Anticancer Drug Compounding in Hospital Pharmacy Practice
Keywords:
chatbot, anticancer drug compounding, hospital pharmacy, usabilityAbstract
Anticancer drug compounding is a complex and high-risk process requiring accurate and timely access to information. However, relevant compounding information is often fragmented across multiple sources, making it difficult to access during routine practice. This study aimed to develop and preliminarily evaluate the usability of MedMixBot, a chatbot designed to support access to anticancer drug compounding information in hospital pharmacy practice.
This research and development study employed a one-group posttest design. Twenty-eight pharmacists from eight hospitals participated in the study. MedMixBot contained a knowledge base covering 10 anticancer drugs, and all participants evaluated all 10 drugs using a 5-point Likert scale questionnaire across four domains: Clarity, Perceived Accuracy, Ease of Understanding, and Attractiveness. Data were analyzed using descriptive statistics.
The results demonstrated high usability based on 280 drug-specific evaluations (28 participants × 10 drugs), with mean scores across all domains (4.70–4.78 out of 5), with Perceived Accuracy receiving the highest score (4.78 ± 0.47). More than 95% of responses were rated in the high range (4–5).
Conclusion: MedMixBot demonstrated high preliminary usability and has the potential to support access to anticancer drug compounding information in hospital pharmacy practice.
References
Institute for Safe Medication Practices. ISMP guidelines for safe medication use in perioperative and procedural settings. Horsham (PA): Institute for Safe Medication Practices; 2022.
United States Pharmacopeia. General chapter <797>: pharmaceutical compounding—sterile preparations. Rockville (MD): United States Pharmacopeia; 2020.
National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2020. Cincinnati (OH): NIOSH; 2023.
Vigneron J, D’Huart E, Demoré B. Stability studies in oncology: a marketing tool for pharmaceutical companies, a scientific mission for hospital pharmacists. Eur J Oncol Pharm 2019;2(2):e12.
Mathaiyan J, Jain T, Dubashi B, Reddy KS, Batmanabane G. Prescription errors in cancer chemotherapy: omissions supersede potentially harmful errors. J Pharmacol Pharmacother 2015;6(2):83–7.
Laranjo L, Dunn AG, Tong HL, Kocaballi AB, Chen J, Bashir R, et al. Conversational agents in healthcare: a systematic review. J Am Med Inform Assoc 2018;25(9):1248–58.
Tudor Car L, Dhinagaran DA, Kyaw BM, Kowatsch T, Joty S, Theng YL, et al. Conversational agents in health care: scoping review and conceptual analysis. J Med Internet Res 2020;22(8):e17158.
Lecoutre C, Vasseur M, Courtin J, Hammadi S, Decaudin B, Odou P. A prospective single-centre study of augmented reality for improving safety in cancer drug compounding. Heliyon 2024;10(13):e32683.
Pupong K, Hunsrisakhun J, Pithpornchaiyakul S, Naorungroj S. Development of chatbot-based oral health care and evaluation: a mixed methods study. JMIR Pediatr Parent 2025;8:e62738.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
การละเมิดลิขสิทธิ์ถือเป็นความรับผิดชอบของผู้ส่งบทความโดยตรง
ผลงานที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของผู้นิพนธ์ ขอสงวนสิทธิ์มิให้นำเนื้อหา ทัศนะ หรือข้อคิดเห็นใด ๆ ของบทความในวารสารไปเผยแพร่ทางการค้าก่อนได้รับอนุญาตจากกองบรรณาธิการ อย่างเป็นลายลักษณ์อักษร
